Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Department of Cytobiology and Proteomics, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Int J Mol Sci. 2020 May 2;21(9):3222. doi: 10.3390/ijms21093222.
Blood platelets play a crucial role in the early stages of atherosclerosis development. The process is believed to require firm adhesion of platelets to atherosclerosis-prone sites of the artery. However, little evidence exists regarding whether the blood platelets of individuals with pathological conditions associated with atherosclerosis have higher potential for adhesion. This process is to a large extent dependent on receptors present on the platelet membrane. Therefore, the aim of the presented study was to determine whether blood platelets from diabetic patients have higher capacity of adhesion under flow conditions and how diabetes affects one of the crucial platelet receptors involved in the process of adhesion-GPIIIa. The study compares the ability of platelets from non-diabetic and diabetic humans to interact with fibrinogen and von Willebrand factor, two proteins found in abundance on an inflamed endothelium, under flow conditions. The activation and reactivity of the blood platelets were also characterized by flow cytometry. Platelets from diabetic patients did not demonstrate enhanced adhesion to either studied protein, although they presented increased basal activation and responsiveness towards low concentrations of agonists. Platelets from diabetic patients were characterized by lower expression of GPIIIa, most likely due to an enhanced formation of platelet-derived microparticles PMPs, as supported by the observation of elevated concentration of this integrin and of GPIIIa-positive PMPs in plasma. We conclude that altered functionality of blood platelets in diabetes does not increase their adhesive potential. Increased glycation and decrease in the amount of GPIIIa on platelets may be partially responsible for this effect. Therefore, higher frequency of interactions of platelets with the endothelium, which is observed in animal models of diabetes, is caused by other factors. A primary cause may be a dysfunctional vascular wall.
血小板在动脉粥样硬化发展的早期阶段发挥着关键作用。人们认为,这一过程需要血小板牢固地黏附在动脉粥样硬化易发生的部位。然而,关于是否存在与动脉粥样硬化相关的病理条件的个体的血小板具有更高的黏附潜力的证据很少。这一过程在很大程度上取决于血小板膜上存在的受体。因此,本研究的目的是确定糖尿病患者的血小板在流动条件下是否具有更高的黏附能力,以及糖尿病如何影响参与黏附过程的关键血小板受体之一-GPIIIa。该研究比较了非糖尿病和糖尿病患者的血小板与纤维蛋白原和血管性血友病因子(在炎症内皮中大量存在的两种蛋白质)在流动条件下相互作用的能力。还通过流式细胞术对血小板的激活和反应性进行了表征。尽管糖尿病患者的血小板表现出对低浓度激动剂的基础激活和反应性增加,但它们并没有表现出对两种研究蛋白的增强黏附能力。糖尿病患者的血小板表现出 GPIIIa 的表达降低,这很可能是由于血小板衍生的微颗粒(PMP)的形成增强所致,这一假设得到了观察到该整合素和 GPIIIa 阳性 PMP 在内皮细胞中的浓度升高的支持。我们得出结论,糖尿病中血小板功能的改变不会增加其黏附潜力。血小板上的糖基化增加和 GPIIIa 数量减少可能是造成这种影响的部分原因。因此,在糖尿病的动物模型中观察到的血小板与内皮细胞的相互作用频率增加是由其他因素引起的。一个主要原因可能是血管壁功能障碍。
World J Diabetes. 2021-7-15
Antioxidants (Basel). 2021-4-29
Platelets. 2017-5
Arch Physiol Biochem. 2017-2
Cardiovasc Diabetol. 2016-3-31